Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Retatrutide - Eli Lilly and Company

Next Previous
Drug Profile

Retatrutide - Eli Lilly and Company

Alternative Names: GGG Tri-agonist - Eli Lilly and Company; GLP-1/GIP/glucagon tri-agonist - Eli Lilly and Company; LY-3437943

Latest Information Update: 13 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Eli Lilly and Company; Hudson Biotech
  • Class Analgesics; Antihyperglycaemics; Antirheumatics; Cardiovascular therapies; Hepatoprotectants; Obesity therapies; Peptides; Sleep disorder therapies; Urologics
  • Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Back pain; Cardiovascular disorders; Non-alcoholic fatty liver disease; Obesity; Osteoarthritis; Sleep apnoea syndrome; Type 2 diabetes mellitus
  • Phase II Renal failure

Most Recent Events

  • 05 Aug 2026 Eli Lilly and Company announces intention to submit BLA to the US FDA for Obesity, Sleep apnoea syndrome and Osteoarthritis in the first quarter of 2027
  • 23 Jul 2026 Efficacy and adverse event data from a phase III TRIUMPH-3 trial in Obesity and Cardiovascular disease released by Eli Lilly and Company
  • 23 Jul 2026 Efficacy and adverse event data from a phase III TRIUMPH-2 trial in Obesity released by Eli Lilly and Company

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top